Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, Gilchrist IC, Kleiman NS, Labinaz M, Madan M, Hafley GE, Califf RM, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators. O'Shea JC, et al. Among authors: cohen dj, cohen ea. JAMA. 2002 Feb 6;287(5):618-21. doi: 10.1001/jama.287.5.618. JAMA. 2002. PMID: 11829701 Clinical Trial.
Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
Blankenship JC, Tasissa G, O'Shea JC, Iliadis EA, Bachour FA, Cohen DJ, Lui HK, Mann T 3rd, Cohen E, Tcheng JE; ESPRIT Investigators. Blankenship JC, et al. Among authors: cohen dj, cohen e. J Am Coll Cardiol. 2001 Sep;38(3):653-8. doi: 10.1016/s0735-1097(01)01423-1. J Am Coll Cardiol. 2001. PMID: 11527612 Free article. Clinical Trial.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. Among authors: cohen dj, cohen ea. JAMA. 2003 Feb 19;289(7):853-63. doi: 10.1001/jama.289.7.853. JAMA. 2003. PMID: 12588269 Clinical Trial.
Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial.
Russo JJ, Goodman SG, Cantor WJ, Fitchett D, Heffernan M, Borgundvaag B, Ducas J, Cohen EA, Džavik V, Mehta SR, Buller CE, Yan AT; TRANSFER-AMI investigators. Russo JJ, et al. Among authors: cohen ea. Heart. 2014 Jun;100(11):873-80. doi: 10.1136/heartjnl-2013-305231. Epub 2014 Jan 21. Heart. 2014. PMID: 24449716 Clinical Trial.
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM. Topol EJ, et al. Lancet. 1999 Dec 11;354(9195):2019-24. doi: 10.1016/s0140-6736(99)10018-7. Lancet. 1999. PMID: 10636365 Clinical Trial.
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Lincoff AM, et al. Among authors: cohen dj, cohen ea. JAMA. 2004 Aug 11;292(6):696-703. doi: 10.1001/jama.292.6.696. JAMA. 2004. PMID: 15304466 Clinical Trial.
391 results